Cannabis Europa London 2026 Opens as First Major Industry Event Post-Rescheduling

Conference Timing Aligns With Post-Rescheduling Market Reset

Cannabis Europa London 2026 convened in late May, roughly four months after the DEA's final rule moved cannabis from Schedule I to Schedule III took effect. The conference, held annually in London, typically attracts 1,500-2,000 attendees from European and North American markets. This year's event drew heightened interest due to timing: the first chance for industry stakeholders to gather at scale since the U.S. regulatory framework shifted in January 2026.

Rescheduling eliminated the Section 280E tax burden for U.S. cannabis operators. Industry analysts projected the change would unlock $1.5 billion to $2 billion in annual tax savings for publicly traded multi-state operators alone. For full background on this story, see the CannIntel topic hub on DEA rescheduling.

European Operators Eye U.S. Market Entry Post-280E

European cultivators and pharmaceutical firms used the conference to explore U.S. market-entry strategies now that federal tax treatment has improved. Panel discussions focused on cross-border investment structures, state licensing pathways, and intellectual property protections for EU-developed cultivars.

German and Swiss operators signaled particular interest in U.S. partnerships. Germany's adult-use framework, implemented in stages since 2024, created a cohort of licensed producers now seeking international expansion. The 280E repeal makes U.S. state-licensed operators viable acquisition or partnership targets for the first time.

Institutional Capital Presence Increases Year-Over-Year

Attendance by institutional investors rose about 30% compared to Cannabis Europa London 2025, according to organizer Prohibition Partners. Hedge funds, private equity firms, and family offices sent senior partners rather than junior analysts. Conference organizers attributed the shift to improved regulatory clarity in the U.S.

Key investor concerns discussed on panels included:

• State-federal licensing conflicts that persist despite rescheduling
• Banking access limitations under federal law
• Interstate commerce restrictions and their impact on consolidation
• Valuation compression in public MSOs despite tax relief

One London-based fund manager noted that rescheduling addressed profitability but not the structural barriers preventing cannabis companies from listing on major U.S. exchanges.

U.S. MSOs Present Post-280E Financial Models

Multi-state operators used the conference to debut updated financial guidance reflecting 280E savings. Several firms projected EBITDA margin expansion of 15-20 percentage points in fiscal 2026. Curaleaf, Trulieve, Green Thumb Industries, and Cresco Labs each held investor meetings on the conference sidelines.

The presentations emphasized debt reduction and capital allocation rather than aggressive expansion. Most MSOs indicated they'd use tax savings to pay down high-interest debt accumulated during the 280E era, when effective tax rates often exceeded 70% of gross profit.

Trulieve's CFO disclosed in a panel that the company expects to reduce its debt-to-EBITDA ratio from 4.2x to below 3.0x by year-end 2026, assuming stable revenue. Green Thumb Industries projected similar deleveraging.

Regulatory Gaps Remain Despite Schedule III Shift

Conference sessions highlighted that rescheduling resolved tax treatment but left interstate commerce bans, federal banking restrictions, and exchange-listing prohibitions unchanged. These limitations continue to fragment the U.S. market into 38 isolated state programs with incompatible regulations.

A panel of U.S. state regulators from California, New York, and Ohio discussed the operational challenges of state-by-state licensing. California's Department of Cannabis Control representative noted that interstate commerce would require congressional action, not administrative rulemaking. No bill with realistic passage prospects has been introduced in the current Congress.

Banking access remains constrained. Some regional banks have expanded cannabis-related services post-rescheduling, but the SAFE Banking Act hasn't advanced. Most national banks continue to avoid the sector.

What Comes Next: Compliance and Consolidation

Industry participants expect a wave of M&A activity in late 2026 as MSOs use improved balance sheets to acquire distressed operators in key markets. Conference deal-flow discussions centered on California, Illinois, and Florida, where license values have compressed 40-60% since 2023 peaks.

The next major regulatory milestone is the DEA's publication of final Good Manufacturing Practice requirements for Schedule III cannabis, expected in Q3 2026. Those rules will determine whether state-licensed cultivators can meet federal standards without facility overhauls.

We'll be watching three indicators through year-end: MSO debt-reduction velocity, institutional ownership percentages in public cannabis equities, and whether any Nasdaq-listed firm successfully petitions for a cannabis subsidiary listing.